# Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

> **NCT00053040** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Pediatric Brain Tumor Consortium**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** cintredekin besudotox
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00053040
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal of pharmaceutical company support for the investigational drug
- **Last updated:** 2010-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053040, "Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00053040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*